Aberrant signaling pathways in t-cell acute lymphoblastic leukemia

Deborah Bongiovanni, Valentina Saccomani, Erich Piovan

Research output: Contribution to journalReview articlepeer-review


T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease caused by the malignant transformation of immature progenitors primed towards T-cell development. Clinically, T-ALL patients present with diffuse infiltration of the bone marrow by immature T-cell blasts high blood cell counts, mediastinal involvement, and diffusion to the central nervous system. In the past decade, the genomic landscape of T-ALL has been the target of intense research. The identification of specific genomic alterations has contributed to identify strong oncogenic drivers and signaling pathways regulating leukemia growth. Notwithstanding, T-ALL patients are still treated with high-dose multiagent chemotherapy, potentially exposing these patients to considerable acute and long-term side effects. This review summarizes recent advances in our understanding of the signaling pathways relevant for the pathogenesis of T-ALL and the opportunities offered for targeted therapy.

Original languageEnglish
Article number1904
JournalInternational Journal of Molecular Sciences
Issue number9
Publication statusPublished - Sep 5 2017


  • Acute lymphoblastic leukemia
  • Oncogenes
  • PI3K/AKT
  • Targeted therapy

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Aberrant signaling pathways in t-cell acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this